Received Sep 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 1 | — | OT |
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 3 | — | OT |
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 2 | — | OT |
No additional AE; an inadvertent 3rd dose was administered to a 6-month-old patient today, 9/15/2025; This spontaneous report was received from a physician and refers to a 6-month-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On unknown dates in 2025, the patient was vaccinated with first and second doses of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB) (dose, route of administration, anatomical site, lot # and expiration date were not reported) as prophylaxis. Then, on 15-Sep-2025, the patient inadvertently received a third dose of Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB), 0.5 mL, total, (route of administration,anatomical site, lot # and expiration date were not reported) as prophylaxis (inappropriate schedule of product administration). No adverse event. Batch/Lot number is being requested and will be submitted if received.